Ilumya Solution for Injection in Pre-filled Syringe
Tildrakizumab
100 mg/ml
Vetter Pharma-Fertigung GmbH & Co.KG
| Pack size | 1 Pre-filled Syringe (1 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 10036.95 AED |
Indications
Ilumya Solution for Injection in Pre-filled Syringe is used for:
Plaque Psoriasis
Adult Dose
Plaque Psoriasis
Indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
100 mg SC at Weeks 0, 4, and q12Weeks thereafter
Child Dose
<18 years: Safety and efficacy not established
Renal Dose
Administration
Contra Indications
Hypersensitivity reaction to tildrakizumab or to any of the excipients
Precautions
In clinical trials, cases of angioedema and urticaria occurred; if serious hypersensitivity reaction occurs, discontinue treatment immediately and initiate appropriate therapy (see Contraindications)
There is a slight increased risk of infection with patients treated with tildrakizumab in clinical trials; patients with active infections or history of recurrent infections were not included in clinical trials; consider the risks and benefits before prescribing
Immunizations
Before initiating therapy, consider completion of all age appropriate immunizations according to current immunization guidelines
No data are available on the response to live or inactive vaccines
Avoid use of live vaccines
Pretreatment evaluation for tuberculosis
Evaluate patients for TB infection before initiating treatment
Initiate treatment of latent TB before administering tildrakizumab; monitor for signs and symptoms of active TB during and after tildrakizumab
Consider anti-TB therapy before initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed; do not administer to patients with active TB infection
Pregnancy-Lactation
Pregnancy
Data are limited regarding use in pregnant women and are insufficient to inform a drug associated risk of adverse developmental outcomes
Human IgG is known to cross the placental barrier; therefore, tildrakizumab may be transferred from the mother to the fetus
Lactation
No data are available on the presence of tildrakizumab in human milk, the effects on the breastfed infant, or the effects on milk production
Human IgG is known to be present in human milk
Tildrakizumab was detected in the milk of monkeys
Interactions
Adverse Effects
Side effects of Tildrakizumab :
>10%
Upper respiratory infections (14%)
1-10%
Injection site reactions (3%)
Diarrhea (2%)
Mechanism of Action
Humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor
IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses
Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines
Note
Ilumya 100 mg/ml Solution for Injection in Pre-filled Syringe manufactured by Vetter Pharma-Fertigung GmbH & Co.KG. Its generic name is Tildrakizumab. Ilumya is availble in Saudi Arabia.
Farmaco SA drug index information on Ilumya Solution for Injection in Pre-filled Syringe is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.